Evidence map›Paper›PMID 35054239›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Preoperative AI-Driven Fluorescence Diagnosis of Non-Melanoma Skin Cancer.

Victoriya Andreeva, Evgeniia Aksamentova, Andrey Muhachev, Alexey Solovey, Igor Litvinov, Alexey Gusarov, Natalia N Shevtsova, Dmitry Kushkin, Karina Litvinova

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Using the power of artificial intelligence to improve the diagnosis and management of nonmelanoma skin cancer.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Victoriya AndreevaMoscow Regional Research and Clinical Institute (MONIKI), 129110 Moscow, Russia.
Evgeniia AksamentovaMoscow Regional Research and Clinical Institute (MONIKI), 129110 Moscow, Russia.
Andrey MuhachevDeep Smart Light Ltd., 7 Bell Yard, London WC2A 2JR, UK.
Alexey SoloveyDeep Smart Light Ltd., 7 Bell Yard, London WC2A 2JR, UK.
Igor LitvinovDeep Smart Light Ltd., 7 Bell Yard, London WC2A 2JR, UK.
Alexey GusarovDeep Smart Light Ltd., 7 Bell Yard, London WC2A 2JR, UK.
Natalia N ShevtsovaMoscow Regional Research and Clinical Institute (MONIKI), 129110 Moscow, Russia.
Dmitry KushkinDermclinic LLC, Bannyy Pereulok 2c2, 129110 Moscow, Russia.
Karina LitvinovaDepartment of Bioengineering, Imperial College London, South Kensington, London SW7 2BT, UK.ORCID 0000-0003-1110-8589
Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky · RUAston University · GBLomonosov Moscow State University · RUMoscow Power Engineering Institute · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis and treatment of non-melanoma skin cancer remain urgent problems. Histological examination of biopsy material-the gold standard of diagnosis-is an invasive procedure that requires a certain amount of time to perform. The ability to detect abnormal cells using fluorescence spectroscopy (FS) has been shown in many studies. This technique is rapidly expanding due to its safety, relative cost-effectiveness, and efficiency. However, skin lesion FS-based diagnosis is challenging due to a number of single overlapping spectra emitted by fluorescent molecules, making it difficult to distinguish changes in the overall spectrum and the molecular basis for it. We applied deep learning (DL) algorithms to quantitatively assess the ability of FS to differentiate between pathologies and normal skin. A total of 137 patients with various forms of primary and recurrent basal cell carcinoma (BCC) were observed by a multispectral laser-based device with a built-in neural network (NN) "DSL-1". We measured the fluorescence spectra of suspected non-melanoma skin cancers and compared them with "normal" skin spectra. These spectra were input into DL algorithms to determine whether the skin is normal, pigmented normal, benign, or BCC. The preoperative differential AI-driven fluorescence diagnosis method correctly predicted the BCC lesions. We obtained an average sensitivity of 62% and average specificity of 83% in our experiments. Thus, the presented "DSL-1" diagnostic device can be a viable tool for the real-time diagnosis and guidance of non-melanoma skin cancer resection.

Indexed as

artificial intelligencebasal cell carcinomadeep learningdense neural networkfluorescence diagnosticsneural networknon-melanoma skin cancer

Identifiers

PMID35054239
PMCPMC8774306
OpenAlexW4200521335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.